Credevo Articles |

Jul15 0

Functional Service Provider: What the Model Is, When It Works, and What Sponsors Often Get Wrong

The Functional Service Provider (FSP) model gives sponsors something that full-service CROs and pure in-house execution don’t: operational depth in specific markets or functions, without surrendering governance of the study. When sponsors use it well, they get experienced on-ground staff, maintain data and IP control, and run leaner than a full-service model allows. When they […]

Jul05 0

Clinical Trial Start-Up Guide in Asia-Pacific: Regulatory Timelines, Ethics Approval (EC) Processes & IMP Import Requirements

Key takeaways Asia-Pacific (APAC) has become one of the most attractive regions for clinical trials due to patient diversity, strong investigator networks, and lower operational costs. However, clinical trial start-up timelines remain highly fragmented across countries. Singapore remains the fastest and most predictable market for clinical trial activation due to centralized systems, parallel submissions, and […]

Jun25 0

Early Investigator Engagement Strategies in Triple-Negative Breast Cancer Trials

Triple-Negative Breast Cancer (TNBC) remains one of the most aggressive and complex forms of metastatic breast cancer, presenting major challenges for sponsors, investigators, and CROs in oncology drug development. As biomarker-driven therapies, immuno-oncology approaches, and precision medicine strategies rapidly evolve, early investigator engagement has become essential for successful clinical trial execution. Strategic collaboration during protocol […]

Jun15 0

Blockbuster Drugs Are Losing Patent Protection in 2028

As four major blockbuster drugs losing patent protection in 2028, the pharmaceutical industry faces one of the most commercially significant exclusivity cliffs in recent years, with more than $56 billion in annual revenue at stake. For generic and biosimilar sponsors, this is not simply a future market event but a present strategic window that demands […]

Jun05 0

Sanfilippo Syndrome (MPS III): Disease Burden, Treatment Landscape & Research Outlook

Sanfilippo Syndrome, caused by a deficiency in one of four enzymes responsible for breaking down heparan sulfate in the brain, presents across four biochemically distinct subtypes, each with its own genetic origin, rate of progression, and clinical nuance. Despite affecting an estimated 1 in 70,000 births globally, the condition remains without a single approved disease-modifying […]

May25 0

Two gene therapy approvals. Twelve months. One disease that had almost no treatment options just three years ago. That is where Epidermolysis Bullosa (EB) stands today. The field has moved fast. But the work is far from over, and the most important opportunities may still lie ahead. What Is Epidermolysis Bullosa? Epidermolysis Bullosa is a […]

May15 0

Amyotrophic Lateral Sclerosis (ALS):Current Treatment Landscape and Emerging Opportunities

Key Takeaways from this article — Amyotrophic Lateral Sclerosis (ALS) affects approximately 30,000 Americans at any given time, with about 5,000 new diagnoses each year in the US alone. — The global ALS treatment market is in an active growth phase, driven by genetic stratification, biomarker-enabled trials, and a first genotype-specific approval in 2023. — […]

May05 0

Biologics have changed the way we treat diseases. Unlike small-molecule drugs, which are made from chemical compounds with clear structures, biologics are large and complex molecules that come from living organisms. This group includes monoclonal antibodies, recombinant proteins, and the growing area of cell and gene therapy. Biologics allow for better targeting of disease pathways, […]

Apr25 0

Biosimilar Planning: Strategies, Trial Design, And Regulatory Convergence

The global biosimilar market is undergoing a meaningful shift toward an “analytical-first” approach, making rigorous biosimilar planning more critical than ever. Regulatory agencies increasingly accept that comprehensive analytical characterization can establish biosimilarity without requiring large Phase III trials, though this is not yet universally applied across all molecule types. This evolution comes as more than […]

Apr15 0

Latest FDA Bioequivalence Guidelines 2025_Credevo

The pharmaceutical landscape from 2025 onwards will undergo a structural shift driven by the latest FDA bioequivalence guidelines (2025). These guidelines are aimed at tightening study expectations while streamlining regulatory pathways for generics. For generic developers, this evolving BE framework is not just a compliance update. Rather, the new BE framework fundamentally impacts formulation strategy, […]

Functional Service Provider (FSP) in Clinical Trials: What the Model Is, When It Works, and What Sponsors Often Get Wrong

Clinical Trial Start-Up Guide in Asia-Pacific: Regulatory Timelines, Ethics Approval (EC) Processes & IMP Import Requirements

Optimizing Clinical Trials in Triple-Negative Breast Cancer: Biomarker Integration, Recruitment Strategies, and Investigator Engagement

Which Blockbuster Drugs Are Losing Patent Protection in 2028?: A Complete Guide for Generic & Biosimilar Sponsors

Sanfilippo Syndrome (MPS III): Disease Burden, Treatment Landscape & Research Outlook

Epidermolysis Bullosa: A Rare Disease At A Turning Point

Amyotrophic Lateral Sclerosis (ALS): Current Treatment Landscape & Emerging Opportunities

Beyond Small Molecules: Special Considerations in the Design, Conduct, and Oversight of Biologics Clinical Trials

Biosimilar Planning: Strategies, Trial Design, & Regulatory Convergence

Latest FDA Bioequivalence Guidelines 2025: How the New Requirements Shape Your Generic Entry Strategy